Division of Advanced Materials Metrology and Life Sciences, Istituto Nazionale di Ricerca Metrologica (INRIM), 10135 Turin, Italy.
Biosensors (Basel). 2024 Mar 26;14(4):156. doi: 10.3390/bios14040156.
The resazurin assay, also known as the Alamar Blue assay, stands as a cornerstone technique in cell biology, microbiology, and drug development. It assesses the viability of cells through the conversion of resazurin into highly fluorescent resorufin. The resulting fluorescence intensity provides a reliable estimate of viable cell numbers. Cytotoxicity assays, such as the resazurin-based method, play a crucial role in the screening of potential drug candidates and in the assessment of pharmaceutical and chemical toxicity. In recent years, inconsistencies have arisen in pharmacogenomic studies, often due to poorly optimized laboratory protocols. These inconsistencies hinder progress in understanding how substances affect cell health, leading to unreliable findings. Thus, the need for standardized and rigorously optimized protocols is evident to ensure consistent and accurate results in cytotoxicity studies. This manuscript describes a standardized procedure for optimizing resazurin-based viability assays to improve the reliability of cytotoxicity data. This optimization approach focuses on critical experimental parameters and data quality, aiming to achieve a level of measurement imprecision of less than 20%. In conclusion, to address the critical issues of reproducibility and reliability, protocol standardization, such as the one described in this manuscript, can greatly enhance the credibility of cytotoxicity studies, ultimately advancing drug safety assessments.
resazurin 检测法,亦称阿尔玛蓝检测法,是细胞生物学、微生物学和药物研发领域的一项重要技术。它通过将 resazurin 转化为高荧光性的 resorufin,评估细胞的活力。所得荧光强度可可靠估计活细胞数量。细胞毒性检测法,如基于 resazurin 的方法,在筛选潜在药物候选物以及评估药物和化学毒性方面发挥着关键作用。近年来,药物基因组学研究中出现了不一致性,这通常是由于实验室方案优化不当所致。这些不一致性阻碍了对物质如何影响细胞健康的理解,导致结果不可靠。因此,需要标准化和严格优化的方案,以确保细胞毒性研究中结果的一致性和准确性。本文描述了一种优化基于 resazurin 的活力检测法的标准化程序,以提高细胞毒性数据的可靠性。这种优化方法侧重于关键的实验参数和数据质量,旨在实现测量精密度低于 20%的目标。总之,为了解决重现性和可靠性这两个关键问题,像本文所描述的这种方案标准化可以极大地提高细胞毒性研究的可信度,最终推进药物安全性评估。